Sodium Dichloroacetate

Summary

Sodium Dichloroacetate (CHEMBL306823) is a phase-3 clinical-stage small molecule; indicated across 8 conditions including lactic acidosis and head and neck squamous cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 8 conditions
• Clinical trials: 3
• Chemistry: 150.92 Da · C2HCl2NaO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL306823
Name	Sodium Dichloroacetate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	517326
Molecular formula	C2HCl2NaO2
Molecular weight	150.92
InChIKey	LUPNKHXLFSSUGS-UHFFFAOYSA-M

SMILES: C(C(=O)[O-])(Cl)Cl.[Na+]

IUPAC name: sodium 2,2-dichloroacetate

Also known as: Ceresine, CMI X-11S, CPC-211, DCA, Dca sodium, NSC-744479, Sodium dichloroacetate, Sodium salt dichloro-acetate, Sodium salt dichloro-acetate (DCA), SID50112986, SODIUM DICHLOROACETATE, SID144207122

Patent coverage: 559 distinct patent families (1,386 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lactic acidosis	3	MONDO:0006040	EFO:1000036
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
glioblastoma	2	MONDO:0018177	EFO:0000519
heart disorder	2	MONDO:0005267	EFO:0003777
breast neoplasm	2	MONDO:0021100	MONDO:0007254
lung neoplasm	2	MONDO:0021117	MONDO:0008903
pulmonary arterial hypertension	1	MONDO:0015924	EFO:0001361

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004490	PHASE3	COMPLETED	Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis
NCT00004493	PHASE2	COMPLETED	Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia
NCT00500929	PHASE2	COMPLETED	A Clinical Trial in Higher Risk Geriatric Patients Undergoing OHSP

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).